Annual report:
Antibiotic Resistance
In December 2020, Alterity acquired an exclusive world-wide license from UniQuest, the commercialisation company of The University of
Queensland (UQ), for the development and commercialization of novel zinc ionophore technology to combat antimicrobial resistance in superbugs.
Under the license, Alterity has the rights to develop and commercialise therapies that re-sensitize bacteria to antibiotics. The licensed technology
combines Alterity’s PBT2 and other zinc ionophores with commonly used antibiotics to treat infections caused by multidrug resistant bacteria. A
published article in the high-impact journal Science Translational Medicine, showed that PBT2 could reverse antibiotic resistance to critical superbugs and demonstrate efficacy in an animal model of sepsis.
So PBT2 is not dead, but nothing can be told because IMO it is in the process of commercialization.
Annual report: Antibiotic ResistanceIn December 2020, Alterity...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.3¢ | $2.733K | 832.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 32 | 45274833 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 126718541 | 16 |
View Market Depth
| Last trade - 15.57pm 09/08/2024 (20 minute delay) ? |
| ATH (ASX) Chart |